Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer-Reference-Cited by-同舟云学术

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

Published:2016-06 Issue:6 Volume:27 Page:1029-1034
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Michiels S.,Pugliano L.,Marguet S.,Grun D.,Barinoff J.,Cameron D.,Cobleigh M.,Di Leo A.,Johnston S.,Gasparini G.,Kaufman B.,Marty M.,Nekljudova V.,Paluch-Shimon S.,Penault-Llorca F.,Slamon D.,Vogel C.,von Minckwitz G.,Buyse M.,Piccart M.

Funder

Ligue Nationale Contre le Cancer

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/6/1029/16701533/mdw132.pdf

Reference42 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers—a review;Ravdin;Gene,1995